Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Yoshimi Matsuda"'
Autor:
Asako Miura, Yoshimi Matsuda, Ikue Ogawa, Junko Takagai, Kazue Hirai, Yukie Hosoda, Shizue Suzukz, Kazuko Onishi
Publikováno v:
Asia-Pacific Journal of Oncology Nursing, Vol 2, Iss 3, Pp 136-143 (2015)
Objective: This study aims to assess the knowledge of definition of cancer survivors among Japanese oncology nurses and their roles in long-term cancer survivorship care. Methods: A structured self-administered and self-report questionnaire created b
Externí odkaz:
https://doaj.org/article/480eb685d9134462bfb12e42c612e7ce
Autor:
Takanori Hayasaki, Yoshimi Matsuda, Yasuhiro Hayashi, Kiyoshi Nobori, Hiroyasu Yamamoto, Tadao Akizawa, Takashi Yamada
Publikováno v:
Kidney International Reports
Introduction Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study. Methods This 52-week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d800c748ba340ad4ed168070ccbb35
http://europepmc.org/articles/PMC8484124
http://europepmc.org/articles/PMC8484124
Autor:
Takanori Hayasaki, Kiyoshi Nobori, Yoshimi Matsuda, Tadao Akizawa, Hiroyasu Yamamoto, Yasuhiro Hayashi
Publikováno v:
American Journal of Nephrology. 52:871-883
Introduction: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79f057e83db8456ed76e29895d0af259
https://doi.org/10.1159/000518071
https://doi.org/10.1159/000518071
Autor:
Yasuhiro Hayashi, Tadao Akizawa, Hiroyasu Yamamoto, Yoshimi Matsuda, Takanori Hayasaki, Kiyoshi Nobori
Publikováno v:
American Journal of Nephrology. 52:884-893
Introduction: Erythropoiesis-stimulating agents (ESAs) are the current standard of care for anemia due to chronic kidney disease (CKD) in patients not undergoing dialysis. Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e42b9ed5f9f0df79fbe2fa870e7e29c6
https://doi.org/10.1159/000518072
https://doi.org/10.1159/000518072
Autor:
Hiroyasu Yamamoto, Kentaro Taki, Yasuhiro Hayashi, Kiyoshi Nobori, Yoshimi Matsuda, Takanori Hayasaki, Tadao Akizawa
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 26(2)
This 36-week, open-label, single-arm, phase 3 study investigated the safety and efficacy of molidustat in Japanese patients with renal anemia undergoing peritoneal dialysis. Molidustat was titrated every 4 weeks to maintain Hb levels within the targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff381749029ed4eb3ba2c8760d27ca7
https://pubmed.ncbi.nlm.nih.gov/34310049
https://pubmed.ncbi.nlm.nih.gov/34310049
Autor:
Yasuhiro Hayashi, Takanori Hayasaki, Kentaro Taki, Kiyoshi Nobori, Yoshimi Matsuda, Tadao Akizawa, Hiroyasu Yamamoto
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Erythropoiesis-stimulating agents (ESA) are the standard of care for anaemia due to chronic kidney disease (renal anaemia). Molidustat, a novel hypoxia-inducible factor prolyl hydroxylase (HIF–PH) inhibitor for the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50dd61dbc6f6f2e8755a5b9f2015a6fa
https://doi.org/10.1093/ndt/gfab085.005
https://doi.org/10.1093/ndt/gfab085.005
Autor:
Tadao Akizawa, Yoshimi Matsuda, Takanori Hayasaki, Hiroyasu Yamamoto, Yasuhiro Hayashi, Kiyoshi Nobori
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 25(6)
Molidustat, an orally administered hypoxia-inducible factor prolyl-hydroxylase inhibitor, is under development for the treatment of anemia of CKD. This 24-week, phase 3, single-arm, multicenter study evaluated the efficacy and safety of molidustat in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::782b87aa9fe332d7f7acf3d372303202
https://pubmed.ncbi.nlm.nih.gov/33506635
https://pubmed.ncbi.nlm.nih.gov/33506635
Autor:
Tadao Akizawa, Kazuma Iekushi, Yoshimi Matsuda, Kiyoshi Nobori, Megumi Taguchi, Hiroyasu Yamamoto
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Treatment with subcutaneous erythropoiesis-stimulating agent (ESA) is the standard of care for renal anemia in non-dialysis patients. A hypoxia-inducible factor prolyl-hydroxylase (HF-PH) inhibitor is an oral medication and might
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c120534d8b2e0ec8473ba6412a7b1f01
https://doi.org/10.1093/ndt/gfaa145.p1868
https://doi.org/10.1093/ndt/gfaa145.p1868
Autor:
Hiroyasu Yamamoto, Megumi Taguchi, Tadao Akizawa, Kazuma Iekushi, Kiyoshi Nobori, Yoshimi Matsuda
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Anemia is a common complication of chronic kidney disease (CKD). A hypoxia-inducible factor prolyl-hydroxylase (HF-PH) inhibitor is developing as a new treatment option of renal anemia. Molidustat, an oral HIF-PH inhibitor, stimul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c308c756315208ebafe0693f3fe46be1
https://doi.org/10.1093/ndt/gfaa145.p1866
https://doi.org/10.1093/ndt/gfaa145.p1866
Autor:
Hiroyasu Yamamoto, Takanori Hayasaki, Tadao Akizawa, Yoshimi Matsuda, Yasuhiro Hayashi, Kiyoshi Nobori
Publikováno v:
American Journal of Nephrology. 52:977-978
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b5f35479af5c3dea7522936fdfd25f0
https://doi.org/10.1159/000520156
https://doi.org/10.1159/000520156